McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, et al. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. J Clin Oncol 2023;41:154-162.
PMID: 36603541